Alexey Eliseev

Maxwell Asset Management manages the Maxwell Biotech Venture Fund. The fund focuses on investments in the biotechnology and pharmaceutical sectors with emphasis on therapeutics, industrial biotechnology and agricultural/veterinary applications. Within the therapeutics industry, the Fund focuses on investments in clinical areas of oncology, diseases of the central nervous system and metabolic disorders. The Fund invests in the application of biotechnology for industrial purposes including the production of biofuels and industrial reagents. In addition, the Fund invests in the application of biotechnology to strategically important agricultural products, such as plant growth promoters, crop protectors and animal health products. The Fund invests in public and private companies in North America, Europe and other parts of the world. Maxwell looks for companies: (1) that are developing products and technologies that are synergistic with the Fund's existing portfolio companies (2) with products that can benefit from testing in Russian clinical trial centers and (3) are interested in commercializing innovative therapeutics in the Russian market. The Maxwell Biotech Venture Fund's primary goal is to invest in Russian-based companies that are developing innovative products and technologies for the domestic and global markets. Maxwell also works with and invests in Western companies when they can help them advance their products along the development path, bring innovative products to the Russian market and generate superior return on investment. Typical investments range from $1 million to $10 million per company, depending on the stage of the company and its products. Maxwell is open to syndication with other venture firms. They place priority on investments that are likely to lead to a financial exit within 5 years.

Maxwell Asset Management is an active manager which provides equity financing in companies located in Russia. The firm targets companies operating in the life sciences sector with a focus on biotechnology, therapeutics, and high-tech medical devices. It invests in early-stage capital requirements with an investment amount of up to USD 5 million in a single company.

Develops immunotherapies for cancer treatment

Operates as a chronic disease hospital

Develops and manufactures molecule pharmaceuticals for arthritic and metabolic diseases

Operates as a biopharmaceutical company, which develops and markets drugs

Provides scientific and technological services